A new hope with amazing results
Do you or someone you know have an excessive urge of hand washing, frequent checking to ensure if the door is locked, or changing clothes every time they go to the washroom? Understandably, none of these actions are happy works and the repetitive deeds of these activities can be truly challenging.
There is still too much left to understand about the pathophysiology of this condition, but the neurophysiological characteristics suggest that OCD is a brain-based anxiety disorder that causes repeated unwanted thoughts or sensations (obsessions) which might or might not seem logical.
This mental health disorder can affect people from all walks of life and across all ages. People with OCD generally have thoughts or actions which:
Obsessions are unwanted, invasive thoughts, urges or images that trigger strongly upsetting beliefs and opinions. What separates OCD obsessions from normal obsessions is their intensity, frequency and their level of discomfort.
Compulsions are behaviors which these individuals take on themselves attempting to eliminate their obsessions and/or decrease his or her distress. These repeated behaviors or thoughts aid these patients in feeling safer. Unfortunately, these compulsive behaviors do not actually prove useful instead get in the way of work, social obligations and daily life.
There are four basic categories into which OCD is classified. They are:
BrainsWay introduced the first FDA cleared (De-Novo) non-invasive medical device for the treatment of OCD. It is the only FDA approved Deep TMS™ treatment available when looking for non-medicative and non-invasive alternative options. The Brainsway technology and proprietary H7-coil magnetvective system works by stimulating the frontal lobes of the brain.
Brainsway has shown proven result in treating OCD symptoms. This outpatient procedure does not take any more than 30 minutes and rarely do patients experience side effects.
The BrainsWay’s Deep-TMS study showed results after six weeks of treatment. It is the only multi-center trial in OCD patients ever conducted and showed significant improvement in the primary endpoint results for the active treatment group when compared to sham (p=0.0127). The primary outcome measure of this study was the OCD Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), which is considered as the gold standard measure of OCD symptom severity.
